{"title":"Computational Tools to Analyze the Pathogenicity and Drug Sensitivity of Oncogenic Mutants.","authors":"Sai Charitha Mullaguri, Sravani Akula, Rama Krishna Kancha","doi":"10.1002/cpz1.70233","DOIUrl":null,"url":null,"abstract":"<p><p>Large-scale genomics efforts led to the identification of an increasing number of mutations in various cancers. However, the functional role of a vast majority of these mutations in disease pathogenesis remains unknown. For enzymes whose activity can be blocked by approved drugs, knowledge regarding the effect of novel or uncommon mutations on inhibitor sensitivity helps in opting for effective treatment strategies. However, it is impossible to experimentally evaluate pathogenic effect and drug sensitivity for all mutations that are being identified in multiple diseases. Therefore, computational predictions of pathogenicity and drug sensitivity can potentially help in the design of an individualized treatment approach. This article includes computational methods to: (a) predict the pathogenicity of mutations based on primary and tertiary structures of the target enzyme, (b) study the effect of mutations on protein conformation, and (c) predict the binding affinity of mutant structures towards targeted therapeutics. All the methods utilize freely available computational tools and have considerable translational value in improving patient outcomes with targeted therapy. © 2025 Wiley Periodicals LLC. Basic Protocol 1: Pathogenicity prediction of mutations based on primary and tertiary structures Basic Protocol 2: Homology modeling of mutant protein structures Basic Protocol 3: Understanding the effect of mutations on protein conformation Basic Protocol 4: Predicting the binding affinities of mutant proteins towards specific inhibitors.</p>","PeriodicalId":93970,"journal":{"name":"Current protocols","volume":"5 10","pages":"e70233"},"PeriodicalIF":2.2000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current protocols","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/cpz1.70233","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Large-scale genomics efforts led to the identification of an increasing number of mutations in various cancers. However, the functional role of a vast majority of these mutations in disease pathogenesis remains unknown. For enzymes whose activity can be blocked by approved drugs, knowledge regarding the effect of novel or uncommon mutations on inhibitor sensitivity helps in opting for effective treatment strategies. However, it is impossible to experimentally evaluate pathogenic effect and drug sensitivity for all mutations that are being identified in multiple diseases. Therefore, computational predictions of pathogenicity and drug sensitivity can potentially help in the design of an individualized treatment approach. This article includes computational methods to: (a) predict the pathogenicity of mutations based on primary and tertiary structures of the target enzyme, (b) study the effect of mutations on protein conformation, and (c) predict the binding affinity of mutant structures towards targeted therapeutics. All the methods utilize freely available computational tools and have considerable translational value in improving patient outcomes with targeted therapy. © 2025 Wiley Periodicals LLC. Basic Protocol 1: Pathogenicity prediction of mutations based on primary and tertiary structures Basic Protocol 2: Homology modeling of mutant protein structures Basic Protocol 3: Understanding the effect of mutations on protein conformation Basic Protocol 4: Predicting the binding affinities of mutant proteins towards specific inhibitors.
分析致癌突变体致病性和药物敏感性的计算工具。
大规模基因组学的努力导致了各种癌症中越来越多的突变的识别。然而,绝大多数这些突变在疾病发病机制中的功能作用仍然未知。对于活性可以被批准的药物阻断的酶,有关新的或不常见的突变对抑制剂敏感性的影响的知识有助于选择有效的治疗策略。然而,不可能通过实验评估在多种疾病中已确定的所有突变的致病作用和药物敏感性。因此,对致病性和药物敏感性的计算预测可能有助于设计个体化治疗方法。本文包括计算方法:(a)根据靶酶的一级和三级结构预测突变的致病性,(b)研究突变对蛋白质构象的影响,以及(c)预测突变结构对靶向治疗的结合亲和力。所有的方法都利用免费的计算工具,在改善患者的靶向治疗结果方面具有相当大的转化价值。©2025 Wiley期刊有限责任公司基本方案1:基于一级和三级结构的突变致病性预测基本方案2:突变蛋白结构的同源性建模基本方案3:了解突变对蛋白质构象的影响基本方案4:预测突变蛋白对特定抑制剂的结合亲和力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。